Innate Pharma S.A. IPHA
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -16.57%
- 1 year
- -26.63%
- Open
- 1.45
- Prev close
- 1.50
- Mkt cap
- 163.08M
- Vol
- 14.78K
- Avg vol
- 159.28K
- EPS
- -0.59
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.45
- High
- 1.48
- Forward P/E
- 4.67
- Beta
- 0.87
- Short ratio
- 5.63
- Inst. own
- 0.50%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 21, 2024
- 50-d avg
- 1.82
- 200-d avg
- 2.23
- 1y target
- 7.41
News
4 days ago businesswire.com
Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca has updated the…
1 week ago businesswire.com
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference.
1 week ago businesswire.com
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma announces conference call for third quarter 2026 business and financial update.
3 weeks ago zacks.com
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in…
3 weeks ago zacks.com
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)
Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in…
1 month ago defenseworld.net
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Target Price of $6.67
Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ: IPHA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six research firms that are presently covering the stock,…
1 month ago zacks.com
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know
Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
1 month ago seekingalpha.com
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
1 month ago marketbeat.com
Innate Pharma Q2 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and…
1 month ago benzinga.com
Innate Pharma H1 2026 Earnings Call Transcript
Innate Pharma (NASDAQ:IPHA) held its quarterly earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive…
1 month ago benzinga.com
Earnings Scheduled For September 17, 2026
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second quarter. • Innate Pharma (NASDAQ:IPHA) is projected to report quarterly loss at $0.16 per share on…
-
1 month ago benzinga.com
Innate Pharma H1 EPS $(0.24) Misses $(0.16) Estimate, Sales $6.583M Miss $9.100M Estimate
Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 14.29 percent increase over losses of…
1 month ago businesswire.com
Innate Pharma Reports First Half 2026 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results…
1 month ago businesswire.com
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously announced…
2 months ago marketbeat.com
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
Innate Pharma NASDAQ: IPHA said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs…
2 months ago seekingalpha.com
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report…
2 months ago businesswire.com
Innate Pharma Announces Conference Call and Webcast
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular session. The market value of their outstanding shares is at $9.5 million. Sionna Therapeutics (NASDAQ:SION)…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics
-
2 months ago benzinga.com
BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9
BTIG analyst Jeet Mukherjee maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $8 to $9.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $5 to $7.
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regular session. The market value of their outstanding shares is at $16.8 million. As per the press release,…
2 months ago benzinga.com
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
Swedish Orphan Biovitrum AB (Sobi) and Innate Pharma SA (NASDAQ:IPHA) on Monday forged a strategic alliance to launch a critical Phase 3 clinical trial targeting a rare form of skin cancer.
2 months ago benzinga.com
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
Sobi and Innate Pharma partner for a Phase 3 trial of lacutamab targeting rare skin cancer, featuring a $75 million upfront payment.
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-market session. The company's market cap stands at $16.8 million. As per the news, the H1 earnings report…
-
2 months ago benzinga.com
Market-Moving News for August 10th
BKYI: -8% | BIO-key And Visualforma Win Contract To Strengthen Digital Identity Security For Portuguese National Security Agency ABCL: 24% | AbCellera Reports Phase 2 Trial Results Showing…
-
2 months ago benzinga.com
Innate Pharma Partners With Sobi To Advance Lacutamab Toward Phase 3, Targets Accelerated Approval Filing In Sézary Syndrome
Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndromeMarkus Jensen appointed Chief…
2 months ago prnewswire.com
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they…
2 months ago businesswire.com
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its…
2 months ago businesswire.com
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®)…
3 months ago seekingalpha.com
Innate Pharma: Pipeline Optionality Favors Speculative Bulls At These Levels
Innate Pharma has an interesting lineup of catalysts with the upcoming IPH4502 data, PACIFIC-9 results, and a potential financing solution for TELLOMAK-3. IPH4502's early responses across several…
3 months ago businesswire.com
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Cancer--Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference.
-
3 months ago benzinga.com
Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data Readout
Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-endFavorable safety profile observed to date, with limited…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
5 months ago benzinga.com
Innate Pharma Advances Lacutamab Phase 3 Trial And IPH4502 ADC Amid €25.4M Cash Runway Through Q3 2026
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation,…
-
6 months ago benzinga.com
Innate Pharma To Present Phase 2 MATISSE Prospectus Data On IPH5201 Combo In Resectable Lung Cancer At AACR 2026
Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and…
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $5 price target.
-
7 months ago benzinga.com
Earnings Scheduled For March 26, 2026
Earnings Scheduled For March 26, 2026
-
7 months ago benzinga.com
Innate Pharma FY EPS $(0.64) Beats $(0.65) Estimate, Sales $10.483M Beat $7.230M Estimate
Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 1.69 percent increase over losses of $(0.65)…
-
7 months ago benzinga.com
BTIG Assumes Innate Pharma at Buy, Announces Price Target of $8
BTIG analyst Jeet Mukherjee assumes Innate Pharma (NASDAQ:IPHA) with a Buy rating and announces Price Target of $8.
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
11 months ago benzinga.com
Innate Pharma Reports €56.4M Cash And €2.3M Nine-Month Revenue As Lacutamab Advances Toward TELLOMAK-3 Phase 3 Initiation In 2026
Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndromeIPH4502 Nectin-4…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
11 months ago benzinga.com
Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
11 months ago benzinga.com
Innate Pharma Gains FDA Clearance To Launch TELLOMAK 3 Phase 3 Trial Of Lacutamab In Sézary Syndrome And Mycosis Fungoides
The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line of…
1 year ago benzinga.com
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday